⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 25, 2019Expert Review of Gastroenterology & HepatologyOpen Access

¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

View Full Paper

Ask AI

Bookmark

Share

Abstract

Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Das et al. (2019) studied this question.

synapsesocial.com/papers/69ff4913831589f3542d816b https://doi.org/10.1080/17474124.2019.1685381

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot StudyFeasibility Study · 2014 · 266 citations
2First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasRetrospective Study · 2010 · 767 citations
3Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine NeoplasmsPrognostic Study · 2019 · 69 citations
4Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesRetrospective Study · 2017 · 3,458 citations
5Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for responseReview · 2017 · 42 citations